News
Regeneron to buy bankrupt 23andMe for $256 million
Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big AI player wants a quarter-million bucks from 23andMe Feds flex 'national security' concerns around 23andMe genetic data Feds flex 'national security' concerns around 23andMe genetic data Biotech was born in the Bay Area 50 years ago.
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 ...
DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...
Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...
After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...
Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...
With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the presentation of 27 abstracts, including eight oral sessions, featuring EYLEA HD (aflibercept) Injection 8 mg at the upcoming ARVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback